Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction
Public ClinicalTrials.gov record NCT00141349. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study to Assess the Time to Onset, Safety, and Toleration of Differing Doses and Combinations of Immediate Release and Modified Release Formulations of UK369,003 in Adult Male Subject With Erectile Dysfunction
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To determine the onset of action, safety and toleration of different formulations and doses of UK-369,003 in patients with erectile dysfunction. Patients should have been previously treated with PDE5 inhibitors and have been responders to the drugs. Duration of treatment is 4 weeks.
Study identification
- NCT ID
- NCT00141349
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 300 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2005 (Type not available)
- Primary completion
- Not listed
- Completion
- Aug 2005 (Type not available)
- Last update posted
- Jul 25, 2006
2005
United States locations
- U.S. sites
- 39
- U.S. states
- 17
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | 35205 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35209-5603 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35215 | — |
| Pfizer Investigational Site | Mesa | Arizona | 85201 | — |
| Pfizer Investigational Site | Mesa | Arizona | 85206 | — |
| Pfizer Investigational Site | Mesa | Arizona | 85213 | — |
| Pfizer Investigational Site | Tempe | Arizona | 85282 | — |
| Pfizer Investigational Site | Beverly Hills | California | 90212 | — |
| Pfizer Investigational Site | San Bernardino | California | 92404 | — |
| Pfizer Investigational Site | Torrance | California | 90505 | — |
| Pfizer Investigational Site | Waterbury | Connecticut | 06708 | — |
| Pfizer Investigational Site | Aventura | Florida | 33180 | — |
| Pfizer Investigational Site | Pembroke Pines | Florida | 33028 | — |
| Pfizer Investigational Site | St. Petersburg | Florida | 33709 | — |
| Pfizer Investigational Site | West Palm Beach | Florida | 33407 | — |
| Pfizer Investigational Site | Evansville | Indiana | 47714 | — |
| Pfizer Investigational Site | Fort Wayne | Indiana | 46825 | — |
| Pfizer Investigational Site | Jeffersonville | Indiana | 47130 | — |
| Pfizer Investigational Site | Metairie | Louisiana | 70002 | — |
| Pfizer Investigational Site | Metairie | Louisiana | 70006 | — |
| Pfizer Investigational Site | Milford | Massachusetts | 01757 | — |
| Pfizer Investigational Site | Kansas City | Missouri | 64114 | — |
| Pfizer Investigational Site | New Brunswick | New Jersey | 08903 | — |
| Pfizer Investigational Site | Albany | New York | 12206 | — |
| Pfizer Investigational Site | Endwell | New York | 13760 | — |
| Pfizer Investigational Site | New York | New York | 10016 | — |
| Pfizer Investigational Site | Raleigh | North Carolina | 27609-7216 | — |
| Pfizer Investigational Site | Raleigh | North Carolina | 27609 | — |
| Pfizer Investigational Site | Winston-Salem | North Carolina | 27103 | — |
| Pfizer Investigational Site | Beachwood | Ohio | 44122-5402 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45212 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44122 | — |
| Pfizer Investigational Site | Bryan | Texas | 77802 | — |
| Pfizer Investigational Site | Sugar Land | Texas | 77478 | — |
| Pfizer Investigational Site | Salt Lake City | Utah | 84109 | — |
| Pfizer Investigational Site | West Jordan | Utah | 84088 | — |
| Pfizer Investigational Site | Norfolk | Virginia | 23502 | — |
| Pfizer Investigational Site | Richmond | Virginia | 23294 | — |
| Pfizer Investigational Site | Milwaukee | Wisconsin | 53209 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00141349, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 25, 2006 · Synced Oct 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00141349 live on ClinicalTrials.gov.